Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001642575-26-000003·Cartesian Therapeutics, Inc.
Schedule 13G ownership disclosure
Cartesian Therapeutics Inc
Common Stock · CUSIP: 816212302
Event date: 2026-03-09
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Squarepoint Ops LLC
Shares: 2,209,601.00 · Class: 8.3%
- Squarepoint Capital LLP
Shares: 2,209,601.00 · Class: 8.3%
- Squarepoint Operations Private Limited
Shares: 2,209,601.00 · Class: 8.3%
- Squarepoint (DIFC) Ltd
Shares: 2,209,601.00 · Class: 8.3%
- Squarepoint Master Fund Limited
Shares: 2,178,652.00 · Class: 8.2%
- Squarepoint Core Master Fund Limited
Shares: 30,949.00 · Class: 0.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001642575-26-000003
- Form type
- SCHEDULE 13G
- Filer
- Cartesian Therapeutics, Inc.
- CIK
- CIK 1453687
- Filed
- Mar 13, 2026
- Reporting period
- Mar 09, 2026
- Description
- Schedule 13G beneficial ownership